Community Studies:

PERL Study

Inclusion Criteria

Participants must be 18 years or older with a diagnosis of Type 1 diabetes and diabetic kidney disease.

Contact

Dawn Lum or Nicole Robinson at 206-209-7491.

Preventing Early Renal Loss in Type 1 Diabetes (PERL) Study group is studying a medication called allopurinol to see if it can prevent the loss of kidney function that occurs in about 1 in 5 people with Type 1 diabetes. The study takes place over 3 and half years and involves 14-17 study visits. Participants will take study medication every day and undergo blood testing every 4 months. To reimburse you for your time and effort in taking part in this study, gift cards will be given for participation.